Stockscreener 앱 받기
133.19
2.40%
3.12
시간 외 거래:
132.00
-1.19
-0.89%
Biogen Inc 주식(BIIB)의 최신 뉴스
Missouri Trust & Investment Co Has $866,000 Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Not Over Yet: Eisai And Lilly To Appeal England’s ‘Flawed’ Refusal To Fund Leqembi And Kisunla - insights.citeline.com
Grimes & Company Inc. Purchases 33,721 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Fifth Third Bancorp Has $751,000 Stake in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen bids to extend use of Skyclarys to younger patients - pharmaphorum
Biogen Dips on Its Part in BRAVE Study - Baystreet.ca
H.C. Wainwright sees potential competition for Sage from Biogen - Yahoo Finance
Biogen (BIIB) Launches Global Phase 3 BRAVE Study for Omaveloxol - GuruFocus
Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia | BIIB Stock News - GuruFocus
Biogen initiates phase 3 trial of omaveloxolone for children with FA - Investing.com
Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia - Biogen
How the Neuroprotection Therapeutics Market Will Evolve by 2032 - openPR.com
Harbor Capital Advisors Inc. Takes Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Targets Rare Diseases, Eyes $800M Cost Cuts With ‘Fit for Growth’ Plan - MSN
Biogen (NASDAQ:BIIB) Seems To Use Debt Quite Sensibly - simplywall.st
Cutaneous Lupus Erythematosus Market Research Report 2025-2035, Competitive Analysis of Biogen, Bristol-Myers Squibb, Sanofi, AstraZeneca, Gilead Sciences, and Kyowa KirinResearchAndMarkets.com - Bluefield Daily Telegraph
Biogen patents new HTT splicing modulators - BioWorld MedTech
Biogen (BIIB) Considers Bid Amid Sage Therapeutics Merger Developments | BIIB Stock News - GuruFocus
Biogen (BIIB) Involved in Sage Pharmaceuticals Acquisition Deal | BIIB Stock News - GuruFocus
Biogen (BIIB) Eyes Contingent Value in Sage Deal | BIIB Stock News - GuruFocus
Bill Nye joins fireside chat supporting Biogen’s Cannes Lion-winning work - Medical Marketing and Media
NorthCrest Asset Manangement LLC Grows Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Supernus makes depression drug play with $795m Sage buyout - Pharmaceutical Technology
Supernus strikes deal to buy Sage Therapeutics - The Business Journals
After rebuffing Biogen, Sage pairs off with Supernus - pharmaphorum
Sage’s Story Comes to ‘Good End’ With Up To $795M Acquisition by Supernus - BioSpace
After brushing off Biogen, Mass. biotech firm finds buyer for $795M - NBC Boston
Maryland firm outbids Biogen for Sage Therapeutics - The Business Journals
Supernus enters depression drug market with up to $795 million Sage deal - MarketScreener
Biogen (BIIB) Gains from Supernus-Sage Therapeutics Acquisition | BIIB Stock News - GuruFocus
Supernus Pharmaceuticals To Acquire Sage Therapeutics - citybiz
Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio - GlobeNewswire
Biogen, UCB Present Positive Phase 3 Results for Lupus Drug Candidate at EULAR 2025 - Insider Monkey
Biogen's (BIIB) "Neutral" Rating Reaffirmed at Piper Sandler - MarketBeat
Pallas Capital Advisors LLC Purchases 7,694 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
From Kentucky farm to founding Biogen: New documentary traces life of Phil Sharp - The Business Journals
Neuroregeneration Therapy Market Know the Scope and Trends | - openPR.com
Data at EULAR back Biogen, UCB's first-in-class lupus drug - pharmaphorum
Biogen Requests to Dismiss Class Action Filed by Investors - TradingView
Biogen (BIIB) Rating and Price Target Reiterated by Piper Sandle - GuruFocus
Biogen (BIIB) Rating and Price Target Reiterated by Piper Sandler Analyst | BIIB Stock News - GuruFocus
Biogen, UCB Take A Leap In Lupus With Promising Phase 3 ResultsBiogen (NASDAQ:BIIB) - Benzinga
Biogen (NASDAQ:BIIB) Earns Neutral Rating from Wedbush - MarketBeat
Biogen (BIIB) Receives Neutral Rating With Price Target Maintained | BIIB Stock News - GuruFocus
Biogen: positive Phase 3 data in lupus - marketscreener.com
Biogen (NASDAQ:BIIB) Receives Hold Rating from Needham & Company LLC - MarketBeat
Demystifying Biogen: Insights From 11 Analyst Reviews - Benzinga
Global Tardive Dyskinesia Treatment Market 2025 | - openPR.com
Biogen (BIIB) Shares Promising Phase 3 Study Results for Lupus D - GuruFocus
Biogen (BIIB) Rating Reiterated as Hold by Needham Analyst | BIIB Stock News - GuruFocus
Biogen (BIIB) Shares Promising Phase 3 Study Results for Lupus Drug Candidate | BIIB Stock News - GuruFocus
Is Biogen Stock Underperforming The S&P 500? - Barchart.com
Is Biogen Stock Underperforming the S&P 500? - The Globe and Mail
0.53%
0.20%
자본화:
|
볼륨(24시간):